Blood heregulin and its relation with efficacy of EGFR-tyrosine kinase inhibitor in EGFR-mutant non-small cell lung cancer

Blood heregulin and its relation with efficacy of EGFR-tyrosine kinase inhibitor in EGFR-mutant non-small cell lung cancer - Blood heregulin in EGFR-mutant NSCLC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035119

Enrollment

100

Registered

2018-12-10

Start date

2016-10-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EGFR-mutant NSCLC

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Pathologically diagnosed NSCLC 2.Stage 3B/IV, or recurrence of post surgery 3.EGFR mutant 4.EGFR-TKI-naive 5.Blood sampled prior to EGFR-TKI therapy 6.Age >20 years 7.patients with signed informed consent form except dead patients

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
the relation of blood heregulin level with the responsiveness of EGFR-TKI	—

Countries

Japan

Contacts

Public ContactKimio Yonesaka

Kindai University Faculty of Medicine Department of Medical Oncology

yonesaka@med.kindai.ac.jp0723-66-0221

Outcome results